WuXi Biologics Achieves Remarkable Annual Results for 2025

WuXi Biologics (Cayman) Inc., a global leader in Contract Research, Development and Manufacturing Organization (CRDMO), has unveiled its annual results for the fiscal year ending December 31, 2025. The figures released on March 24, 2026, underscore the company’s robust performance, showcasing its transformative journey in the biopharmaceutical industry.

Key Financial Highlights

In 2025, WuXi Biologics achieved a remarkable revenue increase of 16.7% year-over-year to reach RMB 21.8 billion, driven by the strategic "Follow and Win the Molecule" initiative and a growing demand for complex biologics, particularly bispecific antibodies and antibody-drug conjugates (ADCs). Notably, revenue from continuous operations surged beyond 20% compared to the previous year.

The company's IFRS gross profit margin expanded to 46.0%, an increase of 500 basis points, with adjusted gross profit margin improving to 48.8%. This substantial margin growth can be attributed to an optimal business mix, higher capacity utilization, and operational efficiencies gained through digital initiatives.

Earnings before interest, taxes, depreciation, and amortization (EBITDA) rose by 38.1% year-over-year, totaling RMB 9.0 billion. Furthermore, the company’s net profit jumped 45.3% to RMB 5.7 billion, enhancing both basic and diluted earnings per share by nearly 49% compared to 2024.

Business Growth and Project Pipeline

WuXi Biologics recorded a historic high of 209 new integrated projects in 2025, bringing the total to 945. This remarkable growth led to a growing influence in the U.S. biopharma sector, which accounted for nearly half of the new project signings. Among the new projects launched, 74 are in their late stages, establishing the company as a significant player in manufacturing revenue growth.

The expansion of research partnerships and increasing milestone payments supported record revenue streams, collectively exceeding US$4 billion. The demand for CD3 T-cell engager partnerships has also gained traction, confirming WuXi’s pivotal role in revenue-generating biopharma platforms.

Manufacturing and Quality Control

Manufacturing capabilities were also a highlight, with WuXi supporting 74 Phase III projects and 25 commercial manufacturing programs in 2025. The company reported a 100% success rate on process performance qualifications, continuing its commitment to quality and reliability in production.

With plans in the pipeline for future developments including the construction of high-capacity production sites across the U.S. and Singapore, WuXi Biologics aims to bolster its global footprint and further enhance service delivery to clients worldwide.

Looking Ahead

Dr. Chris Chen, CEO of WuXi Biologics, stated, “In 2025, we have demonstrated record and profitable growth, supported by our unique CRDMO model. As we continue to invest in our capabilities, we are well-positioned to cater to the expanding needs of our global partners.”

The company’s focus on sustainability and environmental, social, and governance (ESG) responsibilities also remains a cornerstone of its business ethos, with initiatives aimed at maintaining high standards in manufacturing processes and engaging in community-focused projects.

As WuXi Biologics sets its sights on the future, it is clear that the company not only navigated economic uncertainties but emerged as an industry benchmark for success and innovation within the biotechnology sector. With its ambitious trajectory, the next phase of growth promises to continue the tradition of excellence established in 2025.